Based on the Dyadic International Inc stock forecast from 1 analysts, the average analyst target price for Dyadic International Inc is USD 6.00 over the next 12 months. Dyadic International Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Dyadic International Inc is Slightly Bearish, which is based on 4 positive signals and 7 negative signals. At the last closing, Dyadic International Inc’s stock price was USD 1.21. Dyadic International Inc’s stock price has changed by -0.82% over the past week, -12.32% over the past month and -27.54% over the last year.
No recent analyst target price found for Dyadic International Inc
No recent average analyst rating found for Dyadic International Inc
Company Overview Dyadic International Inc
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida. Read Less
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development ...Read More
Frequently Asked Questions About Dyadic International Inc (DYAI) Stock
Based on ratings from 1 analysts Dyadic International Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on DYAI's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for DYAI is USD 6.00 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 6.
DYAI stock's Price/Earning ratio is 0.70.
Our analysis grades DYAI stock's Price / Earning ratio at C. This means that DYAI stock's Price/Earning ratio is above 26% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this DYAI may be undervalued for its sector.
The last closing price of DYAI's stock was USD 1.21.
The most recent market capitalization for DYAI is USD 0.03B.
Based on targets from 1 analysts, the average taret price for DYAI is projected at USD 6.00 over the next 12 months.
This means that DYAI's stock price may go up by +395.87% over the next 12 months.
We can't find any ETFs which contains Dyadic International Inc's stock.
As per our most recent records Dyadic International Inc has 6 Employees.
Dyadic International Inc's registered address is 1044 North U.S. Highway One, Jupiter, FL, United States, 33477-5094.
You can get more information about it from Dyadic International Inc's website at https://www.dyadic.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Dyadic International Inc (DYAI) Stock
Based on ratings from 1 analysts Dyadic International Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on DYAI's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for DYAI is USD 6.00 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 6.
DYAI stock's Price/Earning ratio is 0.70.
Our analysis grades DYAI stock's Price / Earning ratio at C. This means that DYAI stock's Price/Earning ratio is above 26% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this DYAI may be undervalued for its sector.
The last closing price of DYAI's stock was USD 1.21.
The most recent market capitalization for DYAI is USD 0.03B.
Based on targets from 1 analysts, the average taret price for DYAI is projected at USD 6.00 over the next 12 months.
This means that DYAI's stock price may go up by +395.87% over the next 12 months.
We can't find any ETFs which contains Dyadic International Inc's stock.
As per our most recent records Dyadic International Inc has 6 Employees.
Dyadic International Inc's registered address is 1044 North U.S. Highway One, Jupiter, FL, United States, 33477-5094.
You can get more information about it from Dyadic International Inc's website at https://www.dyadic.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DYAI !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
